Actively Recruiting
Clinical Application of 68Ga-FL-031 PET in the Diagnosis and Staging of Malignant Tumors
Led by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Updated on 2025-12-24
10
Participants Needed
1
Research Sites
67 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The project's objective is to recruit patients with clinically confirmed or suspected small cell lung cancer, breast cancer, nasopharyngeal carcinoma and other tumours for 68Ga-FL-031 PET imaging and 18F-FDG PET imaging. The histopathology of biopsy or surgical specimens was taken as the final diagnostic criteria, and the presence or absence of tumour lesions was confirmed by the aforementioned imaging. The location and nature of the lesion, and the presence or absence of metastasis, were then judged. The objective was to analyse and clarify the diagnostic efficacy of 68Ga-FL-031 PET imaging for the aforementioned malignant tumours. The objective of this study is to analyse the correlation between the 68Ga-FL-031 PET imaging tumour tissue uptake value and the tumour tissue immunohistochemical staining SSTR2 target expression.
CONDITIONS
Official Title
Clinical Application of 68Ga-FL-031 PET in the Diagnosis and Staging of Malignant Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- The subject or their legal representative is permitted to sign the informed consent form.
- The subject agrees to follow all study procedures and cooperate throughout the study.
- Adult patients aged 18 years or older, any gender.
- Patients with clinical suspicion or confirmed diagnosis of small cell lung cancer, breast cancer, nasopharyngeal carcinoma, or other tumors supported by tumor markers, imaging, or histopathology.
- The patient is generally in good condition.
- All parties agree to use the designated specimen for study purposes.
You will not qualify if you...
- The patient or legal representative is unable or unwilling to sign the informed consent.
- The patient cannot cooperate with the entire study.
- The patient has acute systemic diseases or electrolyte disorders.
- Pregnant or breastfeeding women.
- Patients deemed unsuitable due to intolerance to SSTR2 targeted substances or other investigator-identified reasons.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Wuhan Union Hospital
Wuhan, Hubei, China, 430022
Actively Recruiting
Research Team
X
Xiaoli Lan, Professor
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here